Cowen says when you consider the potential of Threshold Pharmaceuticals (THLD -0.2%) pancreatic...


Cowen says when you consider the potential of Threshold Pharmaceuticals (THLD -0.2%) pancreatic cancer drug TH-302, the stock is definitely undervalued. The firm estimates the sales potential for the drug in the U.S. alone is close to $1.5B.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs